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Genetic testing for neurodegenerative diseases (NDs) is highly challenging because of
genetic heterogeneity and overlapping manifestations. Targeted-gene panels (TGPs),
coupled with next-generation sequencing (NGS), can facilitate the profiling of a large
repertoire of ND-related genes. Due to the technical limitations inherent in NGS
and TGPs, short tandem repeat (STR) variations are often ignored. However, STR
expansions are known to cause such NDs as Huntington’s disease and spinocerebellar
ataxias type 3 (SCA3). Here, we studied the clinical utility of a custom-made TGP
that targets 199 NDs and 311 ND-associated genes on 118 undiagnosed patients.
At least one known or likely pathogenic variation was found in 54 patients; 27 patients
demonstrated clinical profiles that matched the variants; and 16 patients whose original
diagnosis were refined. A high concordance of variant calling were observed when
comparing the results from TGP and whole-exome sequencing of four patients. Our
in-house STR detection algorithm has reached a specificity of 0.88 and a sensitivity of
0.82 in our SCA3 cohort. This study also uncovered a trove of novel and recurrent
variants that may enrich the repertoire of ND-related genetic markers. We propose
that a combined comprehensive TGPs-bioinformatics pipeline can improve the clinical
diagnosis of NDs.
Keywords: neurodegenerative diseases, undiagnosed diseases, gene panel, short tandem repeat, clinical
decision support, high-throughput sequencing
INTRODUCTION
Population growth and aging play pivotal roles in dynamic changes in disease patterns. The
increasing average age of the world population is accompanied by an epidemiological shift
in disease burden from communicable to non-communicable diseases, specifically neurological
disorders. Neurodegenerative diseases (NDs) represent a highly heterogeneous group of disorders
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that are characterized by progressive degeneration of the nervous
systems. The major difficulty in diagnosing NDs is the dichotomy
between familial (rare) and common (idiopathic/sporadic) cases.
Although the underlying genetic profiles in sporadic cases are
quite complex, the convoluted clinical symptoms shared among
sporadic ND cases often add to the challenge of diagnosis.
Previous studies have demonstrated the utility of a microarray-
based genotyping approach for the investigation of genetic
variations in NDs (Ghani et al., 2015; Nalls et al., 2015;
Blauwendraat et al., 2017), but microarray approaches are not
well-suited for the detection of insertions and deletions (indels),
short tandem repeats (STRs), and novel variants in disease genes.
Therefore, it is important to explore more advanced technologies
in profiling the genotypes of patients.
The recent advances in next-generation sequencing (NGS)
technologies greatly facilitate the identification of mutations
that cause various forms of hereditary NDs (Tazir et al.,
2014; Tsoi et al., 2014; Yu et al., 2016). Defining the genetic
cause of hereditary NDs via NGS platforms avoids excessive
diagnostic tests, allows patients to receive the most appropriate
clinical care based on the molecular diagnosis, provides the
opportunity for genetic counseling of the patients’ families, and
allows for a more defined set of patients to be recruited for
clinical trials. The three most common clinical NGS diagnostic
approaches include whole-genome sequencing (WGS), whole-
exome sequencing (WES), and targeted NGS (Klein and
Foroud, 2017). Of these three, targeted NGS has become more
popular as a diagnostic methodology in many clinical molecular
diagnostics settings but is still gaining traction as a routine
diagnostic tool in neurological clinics. Compared with WES,
custom-designed NGS panels cause less confusion to clinicians.
After patients have been clinically diagnosed, a defined set
of targeted gene panels can be used to pinpoint the disease-
causing mutation. In contrast, WGS and WES produce large
numbers of variants with uncertain significance or incidental
findings, adding to the challenge of interpreting them in the
clinical setting.
Empowered by affordable NGS technologies, reports have
accumulated in recent years of cases of successful identification
of causative genetic variants underlying a diverse array of
human diseases. We have adopted a targeted-gene approach and
designed a targeted-gene panel (TGP) focusing on 311 genes
that are associated with 199 neurological disorders. Here we
report the design of the TGP and the screening results on 118
consenting patients; we have successfully confirmed clinically
diagnosed cases and identified potentially causative mutations
in unknown ones. Most existing screening methods do not
cover the promoter, untranslated regions (UTRs), or intronic
regions, which are often linked with neurological diseases
(Notebaart et al., 2006; La Spada and Taylor, 2010; Loureiro
et al., 2015). Other existing panels that target NDs, such as the
ONDRISeq panel (80 genes) (Farhan et al., 2016), the TruSeq
Neurodegeneration Panel (118 genes; Illumina Inc) and the panel
proposed by Krüger’s group (277 genes) (Krüger et al., 2016), have
less genes covered and do not support the analysis of STR. We
propose that the extended panel and the bioinformatics analysis
pipeline can support the clinical diagnosis of NDs by delineating
overlapping observations, enabling clinicians to reduce the time
to diagnosis by assessing a wide range of NDs in one test.
MATERIALS AND METHODS
Patient Samples
One hundred eighteen patients were recruited from the adult
neurological disease clinic in the Prince of Wales Hospital.
According to assessments by at least one neurology specialist,
these patients showed various degrees of neurodegeneration, yet
definitive diagnosis was not possible despite having the results of
standard imaging, biochemical, and target-gene tests. This study
was approved by the Joint Chinese University of Hong Kong–
New Territories East Cluster Clinical Research Ethics Committee
(ref. nos. CRE-2012.361). Informed consent was obtained from
all subjects in this study.
Design of a Targeted Enrichment Panel
We curated a catalog of 199 neurodegenerative disorders and
311 associated genes (Supplementary Table S1) from the
Orphanet (INSERM, 1997) and OMIM databases (Hamosh et al.,
2005). We emphasized genes that were implicated in ataxias,
spastic paraplegia (SPG), Charcot-Marie-Tooth (CMT) disease,
amyotrophic lateral sclerosis, and other rare Mendelian NDs.
Genes that are linked to more common NDs, such as Alzheimer’s
disease (AD) and dementia, were included to aid in delineating
the observed symptoms. The TGP covers a total length of
2,453,403 base pairs (bps). The target capture probes for the 6,806
exons, splice regions, UTRs, promoters, and selected introns that
are known to be involved in neurological repeat expansions were
designed using SeqCap NimbleDesign (Roche, Switzerland).
Library Preparation and Sequencing
Genomic DNA molecules of at least 1 µg were isolated
from a subject’s blood using a QIAamp DNA Blood Mini
Kit (QIAGEN Inc). The quantity and quality of the extracted
DNA were assessed by NanoDrop 2000 (Thermo Fisher
Scientific, United States) and Qubit fluorometer (Thermo Fisher
Scientific, United States).
The target-capture method was adapted from Roche SeqCap
EZ Library SR User’s guide Version 5.1. To obtain a larger
dynamic range of DNA STR variation, the insert size of paired
sequencing reads was increased from the default 250 bps
to a median of 350 bps. This required tuning the Covaris
ultrasonoscope (Covaris, United States) to output fragments of
330–370 bps, followed by reducing the PEG/NaCl SPRI solution
ratio to 0.5 volume during the double size selection step with
AMPure beads (Beckman Coulter, United States). Each targeted
region of the human genome was sequenced at a depth of about
200 times using the Illumina NextSeq 500 paired-end 2× 150-bp
high-throughput DNA sequencing platform.
The whole-exome target capture was performed according to
the recommendations of the Roche SeqCap EZ MedExome Kit.
Sequencing of the whole-exome library was performed using the
Illumina MiSeq paired-end 2 × 75-bp high-throughput DNA
sequencing platform.
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Sequence Alignment and Variant Calling
Raw reads were first processed using quality-check programs,
such as Trimmomatic, to perform quality trimming and
remove adapter contaminants. The short-read sequences were
aligned to the human genome (version GRCh38) using
BWA (version 0.7.12) (Li and Durbin, 2009), followed by
PCR duplicates marking, local realignment around indels,
and base quality score recalibration using Picard (version
1.141) and Genome Analysis Toolkit (GATK:version 3.7)
(McKenna et al., 2010).
Single-nucleotide polymorphisms (SNPs) and small indels
were called using methods that we described previously (Tsoi
et al., 2014; Yu et al., 2016), albeit with updated programs
and databases. In brief, calling of SNPs and small indels
was performed using batch genotype calling of all subjects
with GATK v3.7 HaplotypeCaller, which outputs variant sites
that can be observed in at least one subject. The variants
were filtered according to the following parameters: (1) GATK
variant quality filter (PASS); (2) Variants within targeted
regions; (3) Allele frequency in population genetics databases
<0.01, except those with previously reported pathogenicity in
ClinVar (1000 Genome phase 3, GnomAD Exome, NHLBI
Exome Sequencing Project 6500); (4) Copy number variations
(CNVs) were called using Seq2C and CNVkit (Talevich et al.,
2016). In brief, both methods normalize the read depths of
the targeted regions in a population of samples and call
CNVs in regions that show significant deviations in read
depths. CNVkit also adjusts for some common biases, such as
repetitive sequences and GC content, and uses off-target reads to
help detect CNVs.
Short Tandem Repeat (STR) Variation
Calling
Variations of STRs were first assessed using exSTRa (Tankard
et al., 2018). In brief, the exSTRa method assumes that most
of the individuals in a tested cohort (>85%) have a normal
range of STR lengths. The distribution of STR lengths is further
simulated using an empirical method. The statistical significance
of the observed STR length of an individual was assessed using an
average of multiple t-statistics.
The results from exSTRa were far from satisfactory when
applied to our sequencing data. We developed an in-house
method for the detection of STR variations in the SCA3 locus.
We used 11 patients who were screened positive for SCA3 and
36 negative controls for the analysis. The method begins with
the calculation of a read count matrix M using HTSeq (–non-
unique all), where rows correspond to STR loci and columns
correspond to samples. Next, the matrix M is normalized by the
library size of each sample using the trimmed mean of M (TMM)
method (Robinson and Oshlack, 2010). Using the R fitdistrplus
package (version 1.0), we fit the normalized read counts from the
control group to five parametric distributions (normal, uniform,
exponential, logistic, beta, lognormal, and gamma). The Cullen
and Frey graph (see Supplementary Figure S2) revealed that
the normal distribution has the best fit. Maximum likelihood
estimation was used to model the parameters of the normal
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We used a Z-score-based method to determine if the patients
have SCA3.
zi = xi − µˆ
σ
The Z-score threshold (–0.91) was determined from the
turning point of the Receiver Operating Characteristic (ROC)
curve, where the sensitivity and specificity are best balanced.
A negative Z-score below the threshold of –0.91 represents an
expanded SCA3 locus.
Variant Interpretation
Variant annotation was performed using Variant Effect Predictor
and dbNSFP (Liu et al., 2013), which included features such
as population allele frequencies (dbSNP 150, 1000 Genome
phase 3, GnomAD Exome, NHLBI Exome Sequencing
Project 6500), sequence conservation (GERP++, PhyloP,
SiPhy), and functional impact predictions (including, but not
limited to, fathmm-MKL, Sift, PROVEAN, MutationAssessor,
MutationTaster, MetaSVM, and MetaLR).
Our scheme of variant classification closely adheres to the
recommendation by the American College of Medical Genetics
(ACMG) (Richards et al., 2015) and the industry standard among
clinical genetics testing laboratories. This scheme represents a
framework for the interpretation of variants.
The classification scheme applies to variants in genes
associated with diseases. Each variant was individually assessed
in the context of the variant, gene, associated disease, and
patient phenotype.
Sequence variants are classified in one of four categories
(pathogenic, likely pathogenic, benign, and likely benign). If
the variant cannot be classified into one of the four categories
above, it is classified as of uncertain significance. Benign and
likely benign variants are not reported in the report. Pathogenic
and likely pathogenic variants discovered in this study were
confirmed by Sanger sequencing.
RESULTS
Study Design
Altogether, 118 patients with various degrees of neurodegene-
rative features, such as ataxias, neuropathy, and unsteady
gait, were recruited from the adult neurological disease
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FIGURE 1 | Summary of the top 15 variants, clinical symptoms, and demographic profiles of the recruited patients. Columns represent patients and rows represent
genes. The percentage of patients in our cohort having at least one missense, stop gain, frameshift indels, inframe indels, or splice site variation in each gene is
shown on the left. Variants, clinical symptoms and demographic profiles are color-coded according to the legends within the figure.
clinic in the Prince of Wales Hospital (Figure 1). Each
patient was reviewed by at least one specialist in neurology,
but definitive molecular diagnosis was not possible even
though multiple neuroimaging investigations, biopsy,
biochemical tests, and targeted genetic screening had been
performed previously. The cohort demonstrated diverse
neurological symptoms: 14 patients were referred with SCA,
13 patients were referred with Parkinson’s disease (PD),
12 patients were classified as having AD, 12 patients were
classified as having SPG, and 11 patients were pre-diagnosed
with CMT disease. The remaining patients demonstrated
symptoms such as dementia, motor neuron disease, and
muscle atrophy. The full list of patients is available in
Supplementary Table S2.
We designed a TGP to cover most genomic regions that
have been implicated in NDs, which helps to provide additional
molecular genetics information for the refinement of diagnosis.
The focused scope of our TGP allows accurate interrogation
of genomic variants through deep sequencing and alleviates
the uncertainty of diagnosis by including genes with proven
clinical value while maintaining a relatively low cost. The
TGP covers 6,806 exons, splice regions, UTRs, promoters,
and selected introns that have been implicated in ND. Three
hundred eleven genes are associated with 199 neurodegenerative
disorders according to the Orphanet (INSERM, 1997) and OMIM
databases (Hamosh et al., 2005). The full list of NDs covered by
the TGP is provided in Supplementary Table S1.
The Landscape of the Identified Variants
All 118 samples were sequenced using an Illumina NextSeq500
system. The average depth of sequencing was 407.5 ± 36.0,
and 99.2% of targeted bases were covered by at least one read
(Supplementary Figure S1). The average reads mapping rate was
99.7% ± 0.1%. We identified 16,693 small variants, including
13,235 SNPs and 3,458 indels. When compared to dbSNP
release 150, 14,118 variants (84.6%) were previously recorded.
These variants can be further classified into 24 nonsense, 66
frameshift indels, 138 inframe indels, 1,671 missense, 34 splice-
site, 3 starts lost, 1 stop lost, 1,535 synonymous, and 13,221
non-coding variants.
In our cohort of patients, 54 out of 118 (45.8%) cases
demonstrated at least one pathogenic or likely pathogenic
variation according to the ClinVar database (version 20190311).
These cases shared 44 unique pathogenic/likely pathogenic
variants. Upon review by the neurology specialists, 27 cases
showed clinical relevance to the observed symptoms. These
pathogenic variants were also confirmed by Sanger sequencing
(Table 1). The high prevalence of pathogenic/likely pathogenic
variants in our ND cohort demonstrated the utility of panel-
based high-throughput sequencing analysis, which excels in

























Phenotype Gene Variant Reported Relevant specialist investigations MRI performed Final
diagnosis
1 0fd42 36–40 CMT GJB1 NM_000166.6:c.118G > T Likely
Pathogenic
ncs showed demyelination no CMTX1
2 7f225 26–30 CMT GJB1 NM_000166.5:c.-103C > T Pathogenic ncs showed demyelination no CMTX1
3 5316c 6–10 CMT GJB1 NM_000166.5:c.-103C > T Pathogenic ncs showed demyelination no CMTX1
4 59e19 41–45 CMT GJB1 NM_000166.5:c.-103C > T Pathogenic ncs showed demyelination no CMTX1
5 67067 31–35 CMT GJB1 NM_000166.5:c.-103C > T Pathogenic ncs showed demyelination no CMTX1
6 44c80 11–15 CMT GJB1 NM_000166.5:c.-103C > T Pathogenic ncs of LL showed unelicited result no CMTX1
7 b17ef 36–40 CMT GJB1 NM_000166.5:c.-103C > T Pathogenic ncs showed demyelination MRI brain SVD CMTX1






amyloid PET scan positive MRI brain SVD EOAD
9 1da51 46–50 SPG SPAST NM_014946.3:c.1507C> T Pathogenic no MRI brain thinning
corpus callosum
SPG4
10 785f3 61–65 ALS TARDBP NM_007375.3:c.892G > A Likely
Pathogenic
EMG showed neurogenic changes MRI spine normal ALS10
11 9400f 6–10 SPG SCA SACS NM_014363.5:c.[7504C >
T;8132C > T]
Pathogenic ncs showed demyelination MRI brain cerebellar
atrophy
ARSACS
12 3d914 31–35 SCA SYNE1 NM_182961.3:c.[20263C>
T;8889delT]
Pathogenic no MRI brain cerebellar
atrophy
SCAR8
13 e3d6c 46–50 SCA TTBK2 NM_173500.3:c.1306
_1307delGA
Pathogenic no MRI brain cerebellar
atrophy
SCA11
14 e7f6c 16–20 SCA TTBK2 NM_173500.3:c.1329dupA Pathogenic no MRI brain cerebellar
atrophy
SCA11
15 4e074 UNKNOWN SCA PRKCG NM_002739.4:c.301C > T Pathogenic CT brain showed cerebellar atrophy no SCA14
16 b1556 41–45 ALS TARDBP NM_007375.3:c.892G > A Pathogenic no MRI spine normal ALS10
17 f5ca3 41–45 SPG PSEN1 NM_000021.3:c.811C > G Pathogenic no no AD type 3,
with spastic
paraparesis




Pathogenic no no SCA









20 73475 51–55 Leucoence
phalopathy
LRRK2 NM_198578.3:c.7153G> A Pathogenic no no Parkinson
disease 8
21 031b4 56–60 AD LRRK2 NM_198578.3:c.4883G>C Pathogenic no no Parkinson
disease 8
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terms of the breadth of disease coverage when compared to
single-gene tests.
We proceeded to remove common variants (minor allele
frequency <1% in all populations), synonymous variants,
non-coding variants, known sequencing artifacts, known non-
pathogenic variants, and missense variants that are unanimously
predicted to be benign. After these filters were applied, 257
coding variants remained. The top 15 mutated genes are
summarized in Figure 1.
Fourteen genes were mutated in more than two patients
(Figure 1). The SPG7 gene, which is involved in SPG 7, was
mutated in 16 patients (13%). Most of these patients (13 out
of 16) harbored the novel p.Leu8del (NM_003119.3:c.21_23del)
variant in the N-terminal signal peptide region. In addition, nine
patients (8%) had a p.Asp668Tyr (NM_000142.4:c.2002G > T)
variant in the protein kinase domain of FGFR3. In SYNE1, four
variants (p.Gln2986AsnfsTer13, p.Gln6494Arg, p.Arg5551Leu,
p.Ala3030Val) were located in seven patients. KIF7, OFD1, and
ATM are also mutated in >3% of our cohort.
We searched further for other recurrent variants that
can be found in patients with similar symptoms. The search
returned three novel variants. In the first case, we found
three heterozygous carriers (ID: 37834, ID: 8c1f1, ID: ad573)
of WWOX p.Glu66GlyfsTer3 (NM_016373.4:c.196dup).
These three patients had been previously diagnosed with
CMT disease. Next, PEX7 p.Gly41Arg heterozygous variant
(NM_000288.4:c.121G > C) was found in two unrelated patients
(ID: 67067 and ID: a68b4). These two patients demonstrated
neuropathy and senile dementia, respectively. Finally, in two
unrelated patients (ID: 8c1f1 and ID: 37834) who demonstrated
CMT symptoms, we found a novel SURF1 heterozygous
p.Gly257Arg (NM_003172.4:c.769G > A) variant. The predicted
pathogenicity values of the variants were high according to a
majority of predictors. Further experiments were planned to
elucidate the functional role of these mutated genes in NDs.
Variants Are Highly Concordant With
Results From WES
To assess the accuracy and reproducibility of the TGP, we chose
four samples (ID: 76a50, ID: 4b227, ID: ef2d1, and ID: 79026)
that do not belong to the same family to perform WES and to
compare that with the TGP results. A total of 1,998 common
variants were identified, and within them, 1,895 variants were
single-nucleotide variants (SNVs) and 103 were indels. Out of
1,895 SNVs within the four samples shared between the WES
and TGP, 1,894 SNVs were identical, leading to a concordance
rate of 99.94%. For indels, 96 out of 103 variants (93.2%) had
the same indels.
Changes in Sequencing Depth Inform
STR Variations
The detection of STR variations from short reads has been
extremely challenging. Early methods (Gymrek et al., 2012; Cao
et al., 2015) focused on short STR loci that are within the read
length of Illumina’s sequencing platforms. More recently, several
methods have become available to detect STR variations that are
Frontiers in Neuroscience | www.frontiersin.org 6 December 2019 | Volume 13 | Article 1324
fnins-13-01324 December 10, 2019 Time: 15:29 # 7
Yu et al. Targeted-Gene Panel for Neurodegenerative Diseases
beyond the length of sequencing reads. Among these methods,
exSTRa (Tankard et al., 2018) is the only one that supports target
capture–based data, such as WES.
Because our TGP includes capture probes that target
neurological repeat loci, as an extended goal, we set out
to investigate the possibility of detecting neurological repeat
expansions through our platform. To this end, we recruited 11
additional patients who were screened positive for SCA3. The
results of these positive cases were compared to 36 negative
controls in the original cohort to assess the accuracy. The
controls were screened negative for CAG or CTG expansions,
including DRPLA, DM1, DM2, SCA1, SCA2, SCA3, SCA6, SCA7,
SCA8, and SCA12.
Marked STR expansions were detected in 7 out of 11 SCA3
patients (Table 2). However, the predicted expansion locus
was correct in only one of the patients (ID: 3038b). The
low specificity of the predictions could be attributed to the
difficulty in mapping repetitive sequences. In fact, all of the
wrong predictions belong to the class of CAG expansions.
Given that SCA3 involves expansion of CAG triplets, in
other words, exSTRa correctly predicted CAG expansions in
about 64% of cases.
Because we were dissatisfied with the accuracy of exSTRa,
we attempted to build our method. CAG expansions greatly
increase the CG content of the STR loci, causing bias in both
the target-capture and sequencing stages (Benjamini and Speed,
2012; Ekblom et al., 2014). Moreover, the CAG expansions
would lower sequence mappability because of mismatches
with the reference sequence. These factors could manifest
in a drop of the depth of coverage. Indeed, by looking
at the normalized read count between the SCA3 and the
control group (Figure 2), we observed a significant drop
in the normalized read count (Wald test: P = 1.47e-05,
FDR = 4.42e-05).
To check if a sample contained significant SCA3 expansion,
we developed a Z-score-based method to screen the patients.
First, we fitted the normalized read counts from the control
group to a parametric distribution. The Cullen and Frey graph
(Supplementary Figure S3) revealed that the distribution of the
normalized read counts closely resemble a normal distribution.
TABLE 2 | STR expansion predictions on patients with SCA3.
Patient ID Original exSTRa exSTRa Inhouse Inhouse
diagnosis prediction P-value prediction Z-score
2abac SCA3 SCA2 1.00E-04 SCA3 −2.00
3038b SCA3 SCA3 3.00E-04 SCA3 −2.59
A001 SCA3 SCA6,HD 1.00E-04 NA −0.86
A032 SCA3 NA NA SCA3 −2.55
A039 SCA3 NA NA SCA3 −1.28
A097 SCA3 NA NA SCA3 −1.88
A115 SCA3 SCA2,SCA17 1.00E-04 SCA3 −3.50
A140 SCA3 NA NA NA −0.45
B042 SCA3 SCA2,SCA17 2.00E-04 SCA3 −0.92
B180 SCA3 SCA8 1.00E-04 SCA3 −2.47
P126 SCA3 SCA17 1.00E-04 SCA3 −2.31
FIGURE 2 | Distribution of normalized read counts of the SCA3 loci. The read
counts of the controls and the patients with SCA3 were compared using the
Wald test (P = 1.47e-05, FDR = 4.42e-05).
Therefore, we applied the maximum likelihood estimation to
model the read counts as a normal distribution. The Q-Q plot
(Supplementary Figure S4) showed that all data points fall
closely along the diagonal, which signifies a good fit.
Next, we used the mean and standard deviations from
the fitted distribution to calculate a Z-score for each known
SCA3 sample. A highly negative Z-score represents a highly
expanded SCA3 locus. The method achieved an AUC of 0.928
from analyzing the ROC curve (Figure 3). We chose the
turning point of the ROC curve as the Z-score threshold
(–0.91) for SCA3 classification. In other words, any sample
with a score below –0.91 would be classified as SCA3. We
achieved a specificity of 0.88 and a sensitivity of 0.82 in our
cohort (Table 2).
FIGURE 3 | ROC analysis of the in-house SCA3 detection algorithm. The
in-house Z-score method achieved an AUC of 0.928.
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DISCUSSION
This study highlights the utility of panel-based screening for
undiagnosed patients with neurological symptoms. We identified
49 (41.5%) patients who carry at least one pathogenic variation
or likely pathogenic variation. Upon further clinical follow-
up, 27 (22.9%) of these patients demonstrated phenotypes that
matched with the variants (Table 1). Of note, about one third
of our patients presented with complex phenotypes, such as
AD, frontotemporal dementia (FTD), and PD. As complex NDs
are not caused by genetic factors alone, the integration of non-
genetic factors in the clinical decision process could improve the
diagnostic yield.
Refinement of Diagnosis
Due to genetic heterogeneity and overlapping symptoms, the
diagnosis of NDs is highly challenging. For example, there
are over 40 subtypes of spinocerebellar ataxia (SCA). While
progressive ataxia is a common clinical observation of SCA,
each subtype has its own distinctive genetic marker (Soong
and Morrison, 2018). Patients with Huntington’s disease with a
clinical presentation of ataxia are often mistaken for SCA (Dong
et al., 2013). Due to slow progression of many NDs, definitive
clinical features may not appear at onset (Armstrong et al., 2005).
These factors highlight the need of a genetic screening method
that can cover a broad range of genes related to NDs for the
refinement of diagnosis.
Because our TGP allowed the interrogation of variants in 311
genes in one test, it facilitated the refinement of the preliminary
diagnosis of 16 patients (Supplementary Table S1). Here, we
highlight a few cases that involved the discovery of novel variants.
In a female patient (ID: c8376) who was suspected of having
FTD or PD, we found a novel heterozygous PSEN1 p.Val261Ile
variant (NM_000021.4:c.781G > A). This novel variant is not
recorded in population genetics databases, such as 1000 Genome
database Phase III (1000G) and Genome Aggregation Database
(gnomAD). It is located in a highly conserved position within
the presenilin domain. The predicted functional impact of the
variant is high according to multiple in silico predictors. Variants
in PSEN1 cause up to 70% of early-onset AD (Larner and
Doran, 2006). Val261Phe and Val261Leu were discovered in six
families, which perfectly segregated with AD (Farlow et al., 2000;
Rogaeva et al., 2001; Miravalle et al., 2002; Jiménez Caballero
et al., 2008; Gómez-Tortosa et al., 2010; Cruts et al., 2012).
A pathogenic variant (Ala260Val) at the immediate upstream
amino acid position was also found in a Japanese early-onset AD
family (Ikeda et al., 1996). Consistent with these case reports,
the age of onset of our patient was 40. A PET scan revealed
amyloid-β plaque accumulation in the patient. An MRI scan of
the brain showed features that are consistent with small-vessel
disease. Given these pieces of evidence, this novel variant was
classified as a likely pathogenic variant (PM1, PM2, PM5, PP3,
PP4) according to the ACMG guidelines (Richards et al., 2015).
The diagnosis of the female patient (ID: c8376) was thus refined
to early-onset AD.
In a male patient (ID: 0fd42) who was suspected of
having CMT disease, we were able to refine the subtype.
A hemizygous GJB1 (NM_000166.6:c.118G > T) Ala40Ser
variant was discovered in the patient. The novel Ala40Ser variant
was not found in the 1000 Genome database Phase III (1000G) or
the Genome Aggregation Database (gnomAD). The variant was
located at a highly conserved position in the connexin domain.
The predicted pathogenicity is high according to multiple in silico
predictors. Pathogenic variants were also reported in the amino
acids immediately upstream (p.Ala39Val; ClinVar ID: 188136)
and downstream (p.Glu41Asp; ClinVar ID: 21079). Functional
studies of a different substitution at the same amino acid position
(p.Ala40Val) showed that the mutant protein is located in the
Golgi apparatus without contacting the cell membrane, and
might interfere with the formation of gap junctions as a result
of trafficking abnormalities (Yum et al., 2002). Based on multiple
lines of evidence, this novel variant was classified as a likely
pathogenic variant (PM1, PM2, PM5, PP3, PP4) according to the
ACMG guidelines (Richards et al., 2015). Therefore, the diagnosis
of the patient was refined to CMT neuropathy X-linked.
In one patient (ID: 3d914), we observed novel variants
that helped to refine the preliminary diagnosis of cerebellar
degeneration. In 3d914, we observed a novel heterozygous
p.Gln2964AsnfsTer13 variant (NM_182961.3:c.8889delT) that
pairs with a known p.Arg6755Ter likely pathogenic variant
(ClinVar ID: 424802) in SYNE1. This novel variant was not
recorded in population genetics databases. Previous research has
demonstrated that compound heterozygous variants in SYNE1
are linked to SCA autosomal recessive 8 (SCAR8) (Lee et al.,
2014). Indeed, this patient demonstrated classic phenotypes of
SCAR8, including cerebellar atrophy detected by MRI. Here, we
showed that this novel compound heterozygous variant pair can
be classified as pathogenic (PVS1, PM2, PM3, PP4) according to
the ACMG guidelines (Richards et al., 2015).
Similarly, in another patient (ID: 9400f), who displayed
ataxia and spastic gait, we observed a novel SACS p.Ser2711Leu
variant (NM_014363.5:c.8132C > T) in compound heterozygous
configuration with a known pathogenic variant (p.Arg2502∗;
ClinVar ID: 5513). The variant pair can be classified as likely
pathogenic (PM2, PM3, PP3, PP4) according to the ACMG
guidelines (Richards et al., 2015). The patient’s nerve conduction
study showed demyelination, and the MRI scan demonstrated
brain cerebellar atrophy. Both clinical observations of 9400f thus
agree with the diagnosis of autosomal recessive spastic ataxia
of Charlevoix-Saguenay (Engert et al., 2000). Novel variants
identified in this study enriched the repertoire of markers that
are associated with different NDs.
Our TGP platform covers promoter regions that are often
neglected in other panel-based or WES studies. Among all the
known pathogenic variants in the ClinVar database, surprisingly,
the c.-103C > T (ClinVar ID: 217166) non-coding variant in the
5′ UTR of GJB1 was the most recurrent one in the cohort. Six
patients from five families had this variant, which constitutes
4.4% of our patients. Five of those patients were males. Two of
the patients were siblings (ID: 67067 and ID: 59e19), whereas
the rest were unrelated. All of these except patient 5316c had a
family history of CMT disease. The most commonly presented
symptoms of these patients were weakness of distal limb muscles
and decreased nerve conduction velocities, which indicate
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demyelination. In all cases, there were no atypical presentations
of symptoms. The CMT neuropathy scores (CMTNS) (Murphy
et al., 2011) were recorded from the patients. Three patients
were classified as mild (CMTNS ≤ 10), and three patients were
classified as moderate (CMTNS 11–20). Our study confirmed that
the GJB1 c.-103C> T variant in the promoter region was a major
contributor in CMT disease in our cohort. Therefore, existing
CMT diagnosis routines should be refined to include screening
of the GJB1 promoter.
SCA35 Markers Showed Incomplete
Penetrance and Imperfect
Co-segregation
We observed two cases that contrasted with the existing
knowledge of SCA35. Two pathogenic missense variants (D510H
and L517W) in exon 10 of TGM6 had previously been found to
perfectly co-segregate with SCA35 symptoms (Wang et al., 2010;
Li et al., 2013; Guo et al., 2014). The D510H variant was found in a
67-year-old Chinese female (ID: 7688b) who had been previously
diagnosed with AD. The patient was also found to have the ApoE-
ε4/ε4 haplotype, which confers a 25-fold higher risk of late-onset
AD (Bertram et al., 2007). She presented with insidious onset
of short-term memory decline, and her family has a history of
late-onset dementia. Mild brain atrophy was observed on MRI
scan, yet neither cerebellar dysfunction nor cerebellar atrophy
was present. These negative findings suggested the incomplete
penetrance of the D510H marker, and the major contributor to
patient 7688b’s phenotype was the ApoE-ε4/ε4 haplotype.
For the L517W heterozygous variant, we observed two
patients who demonstrated imperfect co-segregation. A 63-year-
old female patient (ID: ef2d1) had a family history of cerebellar
syndrome, and her MRI demonstrated mild cerebellar atrophy.
However, further Sanger sequencing showed only one of her
two affected relatives harbors the L517W variant, suggesting
incomplete co-segregation with the phenotype. An unrelated 46-
year-old male patient (ID: c2356) displayed gait disorder since
age 28 with the clinical finding of spastic paraparesis. At age 37,
progressive bulbar dysfunction appeared. Physical examination
showed facial dystonia and blepharospasm. His MRI showed
symmetrical bilateral T1 hypointense and T2 hyperintense signals
at cerebellar hemispheres around the dentate nucleus with no
contrast enhancement. Slightly prominent cerebellar folia, which
may represent mild atrophic change, were also observed from
MRI. Surprisingly, there was no history of cerebellar symptoms
in the family of patient c2356.
Upon examining population genetics databases, the allele
frequencies of D510H (1000G–0.3%; gnomAD–0.2%) and
L517W (1000G–0.1%; gnomAD–0.2%) in East Asians were
alarmingly high with regard to the incidence rate of SCA in
general. As we were able to obtain three additional samples
from the relatives of patient ef2d1, we first set out to further
investigate if other variants could explain the phenotypes via
WES. Family-based linkage analysis of patient ef2d1’s family (Tsoi
et al., 2014) (Supplementary Figure S2) unexpectedly showed
a negligible linkage disequilibrium (LD) signal at chromosome
20p13-12.2, which was reported as the LD block of SCA35 (Wang
et al., 2010). We further searched for coding variants that fit
the dominant mode of inheritance in the family within 20p13-
12.2, yet all of them are common variants (minor allele frequency
>1%) according to the 1000G and gnomAD databases. Based
on the currently available results, we were unable to pinpoint
the causative variant for this family. Our findings corroborate
with a recent report of unaffected individuals who carry SCA35
markers, and a highly inflated prevalence of pathogenic variants
in TGM6 over the disease incidence rate of SCA (Fung et al.,
2019). Further research may be required to elucidate if there are
additional disease modifiers for SCA35.
Comparison With Other Methods and
Other Studies
Like NDs, the diagnosis of neurometabolic or neuromuscular
syndromes is also impeded by non-specific clinical features.
Using a panel of 614 genes that are related to familial
neurometabolic syndromes, Reid et al. were able to identify the
genetic diagnosis for 8 out of 21 (38%) undiagnosed patients,
despite the absence of biochemical markers (Reid et al., 2016).
In a cohort of 65 patients with spinal muscular atrophies but
without mutation in SMN1, Karakaya et al. (2018) achieved 33%
diagnostic yield with the help of a gene panel that contains 479
genes. These studies achieved a similar level of diagnostic yield
when compared to our study.
Some commonly used sequencing panels for NDs cover a
much smaller number of genes. For instance, Illumina’s TruSeq
Neurodegeneration Panel covers 118 genes that are associated
with seven groups of NDs. Cartagenia’s Treatable Metabolic
Neurodegenerative Disorders panel covers 73 genes and 41
diseases. Meanwhile, ONDRISeq (Farhan et al., 2016) covers only
80 neuro-related genes.
WES and WGS cover a much larger portion of the genome.
The broader scope of WES and WGS cause a higher level of
uncertainty, insofar as many genomic regions have an unknown
association with neurodegeneration and present difficulties
associated with ascertaining the pathogenicity of a large amount
of variants (Xue et al., 2015). Other trade-offs include the
lower depth of coverage and higher cost (Xue et al., 2015;
Reid et al., 2016).
WES and most existing neurodegeneration panels do not
provide good coverage of CAG expansion loci. For instance,
Nascimento et al. reported a case in which the WES result was
normal, even though CAG expansion was present in ATXN7
(Nascimento et al., 2018). Our panel provides coverage of known
neurological repeats loci, which will increase the resolving power
for diagnosis of NDs.
Future Developments
Because of a high false positive rate of discovery, we did not cover
CNVs and structural variations in this study. We envisage that
further improvement in detection algorithms and sequencing
technologies in the future could allow us to screen these variants
as well. Theoretically, our STR expansion detection algorithm
applies to all SCA types. Although we were able to benchmark
the algorithm on patients with SCA3 only, the algorithm can be
easily expanded to other STR expansion types once additional
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training data are available. With the ability to assess small variants
and STR expansions in 311 genes simultaneously, our TGP
platform holds tremendous potential to refine the diagnostic
workflow of NDs.
DATA AVAILABILITY STATEMENT
The raw target-capture sequencing data were deposited to the
European Genome-phenome Archive (EGA) under the accession
EGAD00001005114. The access to the data is controlled due to
privacy concerns. Interested parties can make a request to the
corresponding author, HC, upon acceptance of the data access
agreements on EGA. All variants reported in this article were
submitted to ClinVar under the submission ID SUB5897755.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the Joint Chinese University of Hong Kong–
New Territories East Cluster Clinical Research Ethics
Committee (ref. no. CRE-2012.361). The patients/participants
provided their written informed consent to participate
in this study.
AUTHOR CONTRIBUTIONS
HC, T-FC, AC, and ACY designed the study. AC, LY, WA, TC, LC,
and VM recruited the patients and performed genotyping. ACY,
AKY, LY, TC, and J-WL performed the analysis, interpreted, and
validated the results. ACY, AKY, AC, LY, WA, TC, XL, J-WL, HC,
and T-FC prepared the manuscript. All authors contributed to the
reviewing of the final version.
FUNDING
This work was supported by the CUHK Gerald Choa
Neuroscience Centre Grant 7105306 to HC, a CUHK Direct
Grant 4053242 to T-FC, and the Technology Start-Up Support
Scheme for Universities (TSU14SCI7, TSU15SCI15, and
TSU16SCI16) grant to the Codex Genetics Limited.
SUPPLEMENTARY MATERIAL




Armstrong, R. A., Lantos, P. L., and Cairns, N. J. (2005). Overlap between
neurodegenerative disorders. Neuropathology 25, 111–124. doi: 10.1111/j.1440-
1789.2005.00605.x
Benjamini, Y., and Speed, T. P. (2012). Summarizing and correcting the GC content
bias in high-throughput sequencing.Nucleic Acids Res. 40:e72. doi: 10.1093/nar/
gks001
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., and Tanzi, R. E. (2007).
Systematic meta-analyses of Alzheimer disease genetic association studies: the
AlzGene database. Nat. Genet. 39, 17–23. doi: 10.1038/ng1934
Blauwendraat, C., Faghri, F., Pihlstrom, L., Geiger, J. T., Elbaz, A., and Lesage, S.
(2017). NeuroChip, an updated version of the NeuroX genotyping platform
to rapidly screen for variants associated with neurological diseases. Neurobiol.
Aging 57:247.e9–247.e13. doi: 10.1016/j.neurobiolaging.2017.05.009
Cao, M. D., Balasubramanian, S., and Bodén, M. (2015). Sequencing technologies
and tools for short tandem repeat variation detection. Brief. Bioinform. 16,
193–204. doi: 10.1093/bib/bbu001
Cruts, M., Theuns, J., and Van Broeckhoven, C. (2012). Locus-specific mutation
databases for neurodegenerative brain diseases. Hum. Mutat. 33, 1340–1344.
doi: 10.1002/humu.22117
Dong, Y., Sun, Y.-M., Liu, Z.-J., Ni, W., Shi, S.-S., and Wu, Z.-Y. (2013).
Chinese patients with Huntington’s disease initially presenting with
spinocerebellar ataxia. Clin. Genet. 83, 380–383. doi: 10.1111/j.1399-0004.2012.
01927.x
Ekblom, R., Smeds, L., and Ellegren, H. (2014). Patterns of sequencing coverage
bias revealed by ultra-deep sequencing of vertebrate mitochondria. BMC
Genomics 15:467. doi: 10.1186/1471-2164-15-467
Engert, J. C., Bérubé, P., Mercier, J., Doré, C., Lepage, P., Ge, B., et al. (2000).
ARSACS, a spastic ataxia common in northeastern Québec, is caused by
mutations in a new gene encoding an 11.5-kb ORF. Nat. Genet. 24, 120–125.
doi: 10.1038/72769
Farhan, S. M. K., Dilliott, A. A., Ghani, M., Sato, C., Liang, E., Zhang, M., et al.
(2016). The ONDRISeq panel: custom-designed next-generation sequencing of
genes related to neurodegeneration. NPJ Genomic Med. 1:16032. doi: 10.1038/
npjgenmed.2016.32
Farlow, M. R., Murrell, J. R., Hulette, C. M., and Ghetti, B. (2000). Hereditary lateral
sclerosis and Alzheimer disease associated with mutation at codon 261 of the
presenilin 1 (PS1) gene. Neurobiol. Aging 21:62. doi: 10.1016/S0197-4580(00)
82502-6
Fung, J. L. F., Tsang, M. H. Y., Leung, G. K. C., Yeung, K. S., Mak,
C. C. Y., Fung, C. W., et al. (2019). A significant inflation in TGM6
genetic risk casts doubt in its causation in spinocerebellar ataxia type
35. Parkinsonism Relat. Disord. 63, 42–45. doi: 10.1016/j.parkreldis.2019.
01.013
Ghani, M., Lang, A. E., Zinman, L., Nacmias, B., Sorbi, S., Bessi, V., et al. (2015).
Mutation analysis of patients with neurodegenerative disorders using NeuroX
array. Neurobiol. Aging 36:545.e9-14. doi: 10.1016/j.neurobiolaging.2014.
07.038
Gómez-Tortosa, E., Barquero, S., Barón, M., Gil-Neciga, E., Castellanos, F., Zurdo,
M., et al. (2010). Clinical-genetic correlations in familial Alzheimer’s disease
caused by presenilin 1 mutations. J. Alzheimers Dis. 19, 873–884. doi: 10.3233/
JAD-2010-1292
Guo, Y.-C., Lin, J.-J., Liao, Y.-C., Tsai, P.-C., Lee, Y.-C., and Soong, B.-W.
(2014). Spinocerebellar ataxia 35: novel mutations in TGM6 with clinical
and genetic characterization. Neurology 83, 1554–1561. doi: 10.1212/WNL.
0000000000000909
Gymrek, M., Golan, D., Rosset, S., and Erlich, Y. (2012). lobSTR: a short tandem
repeat profiler for personal genomes. Genome Res. 22, 1154–1162. doi: 10.1101/
gr.135780.111
Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A., and McKusick, V. A.
(2005). Online mendelian inheritance in man (OMIM), a knowledgebase of
human genes and genetic disorders. Nucleic Acids Res. 33, D514–D517. doi:
10.1093/nar/gki033
Ikeda, M., Sharma, V., Mark Sumi, S., Rogaeva, E. A., Poorkaj, P., Sherrington,
R., et al. (1996). The clinical phenotype of two missense mutations in the
presenilin i gene in Japanese patients. Ann. Neurol. 40, 912–917. doi: 10.1002/
ana.410400614
INSERM, (1997). Orphanet: an Online Database of Rare Diseases and Orphan
Drugs. Paris: INSERM.
Jiménez Caballero, P. E., de Diego Boguna, C., Martin Correa, E., Serviá Candela,
M., Marsal Alonso, C., and Marsal Alonso, C. (2008). A novel presenilin 1
Frontiers in Neuroscience | www.frontiersin.org 10 December 2019 | Volume 13 | Article 1324
fnins-13-01324 December 10, 2019 Time: 15:29 # 11
Yu et al. Targeted-Gene Panel for Neurodegenerative Diseases
mutation (V261L) associated with presenile Alzheimer’s disease and spastic
paraparesis. Eur. J. Neurol. 15, 991–994. doi: 10.1111/j.1468-1331.2008.02230.x
Karakaya, M., Storbeck, M., Strathmann, E. A., Delle Vedove, A., Hölker, I.,
Altmueller, J., et al. (2018). Targeted sequencing with expanded gene profile
enables high diagnostic yield in non-5q-spinal muscular atrophies. Hum.
Mutat. 39, 1284–1298. doi: 10.1002/humu.23560
Klein, C. J., and Foroud, T. M. (2017). Neurology individualized medicine: when
to use next-generation sequencing panels. Mayo Clin. Proc. 92, 292–305. doi:
10.1016/j.mayocp.2016.09.008
Krüger, S., Battke, F., Sprecher, A., Munz, M., Synofzik, M., Schöls, L., et al. (2016).
Rare variants in neurodegeneration associated genes revealed by targeted panel
sequencing in a German ALS cohort. Front. Mol. Neurosci. 9:92. doi: 10.3389/
fnmol.2016.00092
La Spada, A. R., and Taylor, J. P. (2010). Repeat expansion disease: progress and
puzzles in disease pathogenesis. Nat. Rev. Genet. 11, 247–258. doi: 10.1038/
nrg2748
Larner, A. J., and Doran, M. (2006). Clinical phenotypic heterogeneity of
Alzheimer’s disease associated with mutations of the presenilin–1 gene.
J. Neurol. 253, 139–158. doi: 10.1007/s00415-005-0019-5
Lee, H., Deignan, J. L., Dorrani, N., Strom, S. P., Kantarci, S., Quintero-Rivera,
F., et al. (2014). Clinical exome sequencing for genetic identification of rare
mendelian disorders. JAMA 312, 1880–1887. doi: 10.1001/jama.2014.14604
Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with burrows-
wheeler transform. Bioinformatics 25, 1754–1760. doi: 10.1093/bioinformatics/
btp324
Li, M., Pang, S., Song, Y., Kung, M., Ho, S.-L., and Sham, P.-C. (2013). Whole
exome sequencing identifies a novel mutation in the transglutaminase 6 gene
for spinocerebellar ataxia in a Chinese family. Clin. Genet. 83, 269–273. doi:
10.1111/j.1399-0004.2012.01895.x
Liu, X., Jian, X., and Boerwinkle, E. (2013). dbNSFP v2.0: a database of human non-
synonymous SNVs and their functional predictions and annotations. Hum.
Mutat. 34, E2393–E2402. doi: 10.1002/humu.22376
Loureiro, J. R., Oliveira, C. L., and Silveira, I. (2015). Unstable repeat expansions in
neurodegenerative diseases: nucleocytoplasmic transport emerges on the scene.
Neurobiol. Aging 39, 174–183. doi: 10.1016/j.neurobiolaging.2015.12.007
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky,
A., et al. (2010). The genome analysis toolkit: a mapReduce framework for
analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303.
doi: 10.1101/gr.107524.110
Miravalle, L., Murrell, J. R., Takao, M., Glazier, B., Piccardo, P., Vidal, R., et al.
(2002). Genetic mutations associated with presenile dementia. Neurobiol. Aging
23:322.
Murphy, S. M., Herrmann, D. N., McDermott, M. P., Scherer, S. S., Shy, M. E.,
Reilly, M. M., et al. (2011). Reliability of the CMT neuropathy score (second
version) in charcot-marie-tooth disease. J. Peripher. Nerv. Syst. 16, 191–198.
doi: 10.1111/j.1529-8027.2011.00350.x
Nalls, M. A., Bras, J., Hernandez, D. G., Keller, M. F., Majounie, E., Renton, A. E.,
et al. (2015). NeuroX, a fast and efficient genotyping platform for investigation
of neurodegenerative diseases. Neurobiol. Aging 36:1605.e7-12. doi: 10.1016/j.
neurobiolaging.2014.07.028
Nascimento, F. A., Raskin, S., Wirth, B., and Teive, H. A. (2018). Beyond
Whole-Exome Sequencing: a propos of two neurodegenerative diseases.
Neurology 90:P5.080.
Notebaart, R. A., van Enckevort, F. H. J., Francke, C., Siezen, R. J., and Teusink,
B. (2006). Accelerating the reconstruction of genome-scale metabolic networks.
BMC Bioinformatics 7:296. doi: 10.1186/1471-2105-7-296
Reid, E. S., Papandreou, A., Drury, S., Boustred, C., Yue, W. W., Wedatilake, Y.,
et al. (2016). Advantages and pitfalls of an extended gene panel for investigating
complex neurometabolic phenotypes. Brain 139, 2844–2854. doi: 10.1093/
brain/aww221
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015).
Standards and guidelines for the interpretation of sequence variants: a joint
consensus recommendation of the American college of medical genetics and
genomics and the association for molecular pathology.Genet.Med. 17, 405–423.
doi: 10.1038/gim.2015.30
Robinson, M. D., and Oshlack, A. (2010). A scaling normalization method for
differential expression analysis of RNA-seq data. Genome Biol. 11:R25. doi:
10.1186/gb-2010-11-3-r25
Rogaeva, E. A., Fafel, K. C., Song, Y. Q., Medeiros, H., Sato, C., Liang, Y., et al.
(2001). Screening for PS1 mutations in a referral-based series of AD cases: 21
novel mutations. Neurology 57, 621–625. doi: 10.1212/WNL.57.4.621
Soong, B. W., and Morrison, P. J. (2018). “Spinocerebellar ataxias,” in Handbook
of Clinical Neurology, eds M. Manto, and T. A. G. M. Huisman, (Amsterdam:
Elsevier), 143–174.
Talevich, E., Shain, A. H. A., Botton, T., Bastian, B. C., Pinkel, D., Segraves, R.,
et al. (2016). CNVkit: genome-wide copy number detection and visualization
from targeted DNA sequencing. PLoS Comput. Biol. 12:e1004873. doi: 10.1371/
journal.pcbi.1004873
Tankard, R. M., Bennett, M. F., Degorski, P., Delatycki, M. B., Lockhart,
P. J., and Bahlo, M. (2018). Detecting tandem repeat expansions in cohorts
sequenced with short-read sequencing data. bioRxiv [preprint]. doi: 10.1101/
157792
Tazir, M., Hamadouche, T., Nouioua, S., Mathis, S., and Vallat, J.-M. (2014).
Hereditary motor and sensory neuropathies or charcot–marie–tooth diseases:
an update. J. Neurol. Sci. 347, 14–22. doi: 10.1016/j.jns.2014.10.013
Tsoi, H., Yu, A. C. S., Chen, Z. S., Ng, N. K. N., Chan, A. Y. Y., Yuen, L. Y. P., et al.
(2014). A novel missense mutation in CCDC88C activates the JNK pathway and
causes a dominant form of spinocerebellar ataxia. J. Med. Genet. 51, 590–595.
doi: 10.1136/jmedgenet-2014-102333
Wang, J. L., Yang, X., Xia, K., Hu, Z. M., Weng, L., Jin, X., et al. (2010). TGM6
identified as a novel causative gene of spinocerebellar ataxias using exome
sequencing. Brain 133, 3510–3518. doi: 10.1093/brain/awq323
Xue, Y., Ankala, A., Wilcox, W. R., and Hegde, M. R. (2015). Solving the molecular
diagnostic testing conundrum for mendelian disorders in the era of next-
generation sequencing: single-gene, gene panel, or exome/genome sequencing.
Genet. Med. 17, 444–451. doi: 10.1038/gim.2014.122
Yu, A. C.-S., Chan, A. Y.-Y., Au, W. C., Shen, Y., Chan, T. F., and Chan, H.-
Y. E. (2016). Whole-genome sequencing of two probands with hereditary
spastic paraplegia reveals novel splice-donor region variant and known
pathogenic variant in SPG11. Mol. Case Stud. 2:a001248. doi: 10.1101/mcs.a00
1248
Yum, S. W., Kleopa, K. A., Shumas, S., and Scherer, S. S. (2002). Diverse trafficking
abnormalities of connexin32 mutants causing CMTX.Neurobiol. Dis. 11, 43–52.
doi: 10.1006/nbdi.2002.0545
Conflict of Interest: ACY and AKY are directors of Codex Genetics Limited.
J-WL, T-FC, and HC are shareholders of Codex Genetics Limited. T-FC and HC
receive compensation as scientific advisors of Codex Genetics Limited.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Yu, Yim, Chan, Yuen, Au, Cheng, Lin, Li, Chan, Mok, Chan and
Chan. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 11 December 2019 | Volume 13 | Article 1324
